| Drug ID: | Drug111 |
|---|---|
| Drug Name: | Dapagliflozin |
| CID: | 9887712 |
| DrugBank ID: | DB06292 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05986136 |
| Molecular Formula: | C21H25ClO6 |
| Molecular Weight: | 408.9 g/mol |
| Isomeric SMILES: | CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl |
| Synonyms: | Dapagliflozin; 461432-26-8; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; dapagliflozine; Dapagliflozina; UNII-1ULL0QJ8UC; 1ULL0QJ8UC; CHEBI:85078; LYN-045; DTXSID20905104 |
| Phase 0: | 5 |
| Phase 1: | 124 |
| Phase 2: | 113 |
| Phase 3: | 175 |
| Phase 4: | 176 |
| Description: | Dapagliflozin is indicated for the management of diabetes mellitus type 2, and functions to improve glycemic control in adults when combined with diet and exercise. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, which prevents glucose reabsorption in the kidney. Using dapagliflozin leads to heavy glycosuria (glucose excretion in the urine), which can lead to weight loss and tiredness. Dapagliflozin was approved by the FDA on Jan 08, 2014. Dapagliflozin is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt938 | 9887712 | Dapagliflozin | 26762 | HAVCR1 | Rattus norvegicus (Norway rat) | 30551545 | Dapagliflozin promotes the reaction [metformin inhibits the reaction [[streptozocin co-treated with fructose] results in increased expression of HAVCR1 protein]]|dapagliflozin inhibits the reaction [[streptozocin co-treated with fructose] results in incre |
| dt939 | 9887712 | Dapagliflozin | 3146 | HMGB1 | Rattus norvegicus (Norway rat) | 33412153 | Dapagliflozin inhibits the reaction [trinitrobenzenesulfonic acid results in increased expression of HMGB1 protein] |
| dt940 | 9887712 | Dapagliflozin | 3162 | HMOX1 | Rattus norvegicus (Norway rat) | 32259528 | Dapagliflozin inhibits the reaction [[fructose co-treated with dietary fats] results in decreased expression of HMOX1 protein]|[atorvastatin co-treated with dapagliflozin] inhibits the reaction [[fructose co-treated with dietary fats] results in decreased |
| dt941 | 9887712 | Dapagliflozin | 3162 | HMOX1 | Rattus norvegicus (Norway rat) | 38997059 | Dapagliflozin inhibits the reaction [doxorubicin results in decreased expression of HMOX1 mrna] |
| dt942 | 9887712 | Dapagliflozin | 3162 | HMOX1 | Rattus norvegicus (Norway rat) | 33412153 | Dapagliflozin inhibits the reaction [trinitrobenzenesulfonic acid results in decreased expression of HMOX1 protein] |
| dt943 | 9887712 | Dapagliflozin | 3309 | HSPA5 | Rattus norvegicus (Norway rat) | 37741535 | Dapagliflozin inhibits the reaction [IL1B protein results in increased expression of HSPA5 mrna] |
| dt944 | 9887712 | Dapagliflozin | 3586 | IL10 | Rattus norvegicus (Norway rat) | 33412153 | Dapagliflozin inhibits the reaction [trinitrobenzenesulfonic acid results in decreased expression of IL10 protein] |
| dt945 | 9887712 | Dapagliflozin | 3600 | IL15 | Rattus norvegicus (Norway rat) | 33882723 | Taxifolin promotes the reaction [dapagliflozin inhibits the reaction [colistin results in increased expression of IL15 protein]]|dapagliflozin inhibits the reaction [colistin results in increased expression of IL15 protein] |
| dt946 | 9887712 | Dapagliflozin | 3553 | IL1B | Rattus norvegicus (Norway rat) | 34939712 | [dapagliflozin co-treated with atorvastatin] inhibits the reaction [[dietary fats co-treated with fructose] results in increased expression of IL1B protein] |
| dt947 | 9887712 | Dapagliflozin | 3553 | IL1B | Rattus norvegicus (Norway rat) | 37741535 | Dapagliflozin inhibits the reaction [IL1B protein results in increased expression of ADAMTS5 protein]|[thapsigargin co-treated with dapagliflozin] inhibits the reaction [IL1B protein results in increased expression of BAX protein]|dapagliflozin inhibits t |
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05986136 | Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease | PHASE2|PHASE3 | RECRUITING | Mostafa Bahaa | Inflammatory Bowel Diseases | DRUG: Mesalamine|DRUG: Dapagliflozin 10mg Tab | Details |
| NCT03863886 | Endoscopic Ultrasound Determines Disease Activity in Crohn's Disease And Ulcerative Colitis | NA | UNKNOWN | Carilion Clinic | Crohn Disease|Ulcerative Colitis | PROCEDURE: Endoscopic ultrasound catheter (UM-2R/… | Details |
| NCT05687474 | Baby Detect : Genomic Newborn Screening | NULL | COMPLETED | Centre Hospitalier Universitaire de Liege | Congenital Adrenal Hyperplasia|Familial Hyperinsu… | None | Details |
| NCT05668013 | A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | PHASE2 | ACTIVE_NOT_RECRUITING | Teva Branded Pharmaceutical Products R&D LLC | Crohn Disease|Colitis, Ulcerative | DRUG: TEV-48574 Dose Regimen A|DRUG: TEV-48574 Do… | Details |
| NCT07168434 | Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome | PHASE3 | RECRUITING | Biocodex | IBS (Irritable Bowel Syndrome)|IBS-D (Diarrhea-pr… | DRUG: Saccharomyces Boulardii 250 MG|DRUG: Placeb… | Details |
| NCT05588843 | Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Sanofi | Colitis Ulcerative | DRUG: SAR443122|DRUG: Placebo | Details |
| NCT05575505 | Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis. | PHASE2 | RECRUITING | Tanta University | Inflammatory Bowel Diseases | DRUG: Pentoxifylline 400 MG | Details |
| NCT05558761 | Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis | PHASE2 | COMPLETED | Tanta University | Inflammatory Bowel Diseases | DRUG: Pentoxifylline 400 MG | Details |
| NCT05549323 | A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis | PHASE1 | TERMINATED | Pfizer | Ulcerative Colitis | DRUG: PF-07054894|DRUG: Placebo | Details |
| NCT05535946 | ABTECT - Maintenance | PHASE3 | ACTIVE_NOT_RECRUITING | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo | Details |
| NCT05509777 | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease | PHASE3 | RECRUITING | Eli Lilly and Company | Crohn's Disease | DRUG: Mirikizumab | Details |
| NCT05507216 | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 | PHASE3 | COMPLETED | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo | Details |
| NCT05507203 | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 | PHASE3 | COMPLETED | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo | Details |
| NCT05499130 | A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | PHASE2 | COMPLETED | Teva Branded Pharmaceutical Products R&D, Inc. | Crohn Disease|Colitis, Ulcerative | DRUG: TEV-48574|DRUG: Placebo | Details |
| NCT05471492 | Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease | PHASE2 | WITHDRAWN | Telavant, Inc. | Crohn Disease | DRUG: Investigational Product|DRUG: Placebo | Details |
| NCT05389709 | A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting | NULL | COMPLETED | Bayer | Functional Gastrointestinal Disorders Such as Irr… | DRUG: Iberogast (STW5-II, BAY98-7410) | Details |
| NCT05377580 | A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis | PHASE2 | COMPLETED | Innovent Biologics (Suzhou) Co. Ltd. | Ulcerative Colitis (UC) | DRUG: Period 1 IBI112 Placebo|DRUG: Period 2 IBI1… | Details |
| NCT05242484 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Janssen Research & Development, LLC | Colitis, Ulcerative | BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… | Details |
| NCT05242471 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | PHASE2 | ACTIVE_NOT_RECRUITING | Janssen Research & Development, LLC | Crohn's Disease | BIOLOGICAL: Guselkumab|BIOLOGICAL: Golimumab|BIOL… | Details |
| NCT05177835 | Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464 | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
No related literature
You can run management commands to establish drug-literature associations